Glp 1 Drugs Are Rewriting America S Food Preferences Says Iff

Glp 1 Drugs Are Rewriting America S Food Preferences Says Iff Eighty five percent of us glp 1 drug consumers report major changes in their food and beverage preferences after starting the medications, says a new report from ingredients giant iff. and it’s not just about cutting down on junk food. Sensory: eighty five percent of glp 1 consumers report significant changes in their food and beverage preferences. common aversions include fatty foods, sweets, deli meats, coffee and alcohol. dry, sticky or dense textures are also frequently rejected.

Glp 1 Drugs Are Rewriting America S Food Preferences Says Iff Glp 1 drugs like ozempic, wegovy, and mounjaro aren’t just reshaping waistlines – they’re rewriting the rules of food culture. what started as a medical breakthrough for diabetes and weight loss has exploded into a lifestyle movement. The report outlines how food and beverage manufacturers can better support the emerging consumer segment of glp 1 medication users with products that align with their evolving preferences. for example, 85% of glp 1 consumers report significant changes in their food and beverage preferences. Despite the rapid rise in glp 1 medication use, most food and beverage products fall short of meeting the needs of these consumers—or aligning with how they now experience food. Iff released a new report highlighting how glp 1 medications are reshaping the sensory experience and nutritional needs associated with eating and drinking. the report outlines how food and beverage manufacturers can support this consumer segment.

Report From Iff Details Opportunities For Serving The Needs Of Glp 1 Despite the rapid rise in glp 1 medication use, most food and beverage products fall short of meeting the needs of these consumers—or aligning with how they now experience food. Iff released a new report highlighting how glp 1 medications are reshaping the sensory experience and nutritional needs associated with eating and drinking. the report outlines how food and beverage manufacturers can support this consumer segment. A new report published by iff provides insights into the impact of glp 1 drugs on the food and beverage industry, and how manufacturers can adapt to new consumer preferences, in particular, their nutritional and sensory needs. A new report by iff details how the rapidly growing glp 1 weight loss consumer market is reshaping the sensory experience and nutritional needs associated with eating and drinking. The rise of glp 1 medications has significantly impacted consumption, and if brands don’t get on board and capture the market share, they risk missing out on a golden opportunity, says iff. Iff, a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing glp 1 consumer market is reshaping the sensory experience and nutritional needs associated with eating and drinking.